Home Cart 0 Sign in  
X

[ CAS No. 63927-22-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 63927-22-0
Chemical Structure| 63927-22-0
Chemical Structure| 63927-22-0
Structure of 63927-22-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 63927-22-0 ]

Related Doc. of [ 63927-22-0 ]

Alternatived Products of [ 63927-22-0 ]

Product Details of [ 63927-22-0 ]

CAS No. :63927-22-0 MDL No. :MFCD04973298
Formula : C9H6BrN Boiling Point : -
Linear Structure Formula :- InChI Key :DPRIHFQFWWCIGY-UHFFFAOYSA-N
M.W : 208.06 Pubchem ID :9859134
Synonyms :

Calculated chemistry of [ 63927-22-0 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 0.0
Molar Refractivity : 49.44
TPSA : 12.89 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.59 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.01
Log Po/w (XLOGP3) : 2.79
Log Po/w (WLOGP) : 3.0
Log Po/w (MLOGP) : 2.3
Log Po/w (SILICOS-IT) : 3.17
Consensus Log Po/w : 2.65

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.56
Solubility : 0.0573 mg/ml ; 0.000275 mol/l
Class : Soluble
Log S (Ali) : -2.72
Solubility : 0.399 mg/ml ; 0.00192 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.56
Solubility : 0.00574 mg/ml ; 0.0000276 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.44

Safety of [ 63927-22-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 63927-22-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 63927-22-0 ]
  • Downstream synthetic route of [ 63927-22-0 ]

[ 63927-22-0 ] Synthesis Path-Upstream   1~22

  • 1
  • [ 119-65-3 ]
  • [ 34784-04-8 ]
  • [ 63927-22-0 ]
  • [ 81045-39-8 ]
Reference: [1] Synthesis, 2002, # 1, p. 83 - 86
  • 2
  • [ 557-21-1 ]
  • [ 63927-22-0 ]
  • [ 362606-11-9 ]
Reference: [1] Patent: WO2016/81290, 2016, A1, . Location in patent: Paragraph 0205
  • 3
  • [ 63927-22-0 ]
  • [ 61563-43-7 ]
Reference: [1] Journal of the American Chemical Society, 1939, vol. 61, p. 183
  • 4
  • [ 3132-99-8 ]
  • [ 22483-09-6 ]
  • [ 58794-09-5 ]
  • [ 63927-22-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 22, p. 6378 - 6382
  • 5
  • [ 6630-33-7 ]
  • [ 22483-09-6 ]
  • [ 63927-22-0 ]
YieldReaction ConditionsOperation in experiment
49.8%
Stage #1: for 3 h; Inert atmosphere; Reflux; Dean-Stark
Stage #2: With aluminum (III) chloride In dichloromethane at 0 - 45℃; for 2 h; Inert atmosphere
A mixture of 2-bromobenzaldehyde (50 g, 270 mmol) , aminoacetaldehyde dimethyl acetal (28.4 g, 270 mmol) and toluene (400 mL) was refluxed under argon. Dehydration was carried out using dean stark for 2.0 hours. After removal of calculated amount of water, the reflux was continued for 1.0 hour. The toluene was evaporated under reduced pressure, the residue was dissolved in dichloromethane (600 mL) , and the solution was cooled to 0°C. To the cooled solution was slowly added aluminium chloride (118.9 g, 891.7 mmol) under argon. The reaction mixture was stirred at 45°C for 2.0 hours. After the completion of the reaction was confirmed by TLC, the mixture was cooled to room temperature and slowly poured into an ice water. The mixture was basified with 10percent sodium hydroxide solution, and the dichloromethane layer was separated. The aqueous layer was re-extracted with dichloromethane (2 x 100 mL) . The combined dichloromethane layers were washed with brine, and dried over sodium sulfate. The dichloromethane was evaporated, and the residue was purified by silica gel (100-200 mesh) column chromatography 5 with 8-12percent. ethyl acetate in hexane as a mobile phase to give the title compound as an off-white solid (28 g, 49.8percent). MS(ESI)m/z: 208 [M (79Br)+l] ,210 [M (81Br)+l]; XH NMR (400 MHz, DMSO-d5) : δ 7.17 (t, J= 7.8 Hz, 1H) ; 7.91 (d, J= 6.0 Hz, 1H) ; 8.02 (d, J = 8.4 Hz, 1H) ; 8.05 (d, J = 8.8 Hz, 1H) ; 8.65 10 (d, J = 5.2 Hz, 1H) 9.48 (s, IH) .
Reference: [1] Patent: WO2016/21742, 2016, A1, . Location in patent: Paragraph 0222; 0223
  • 6
  • [ 1239460-78-6 ]
  • [ 63927-22-0 ]
Reference: [1] Patent: WO2010/91310, 2010, A1, . Location in patent: Page/Page column 102
  • 7
  • [ 23687-27-6 ]
  • [ 63927-22-0 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 15, p. 4972 - 4982
  • 8
  • [ 34784-04-8 ]
  • [ 63927-22-0 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 15, p. 4972 - 4982
  • 9
  • [ 63927-23-1 ]
  • [ 63927-22-0 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 15, p. 4972 - 4982
  • 10
  • [ 14000-31-8 ]
  • [ 645-36-3 ]
  • [ 6630-33-7 ]
  • [ 63927-22-0 ]
Reference: [1] Patent: US2002/6923, 2002, A1,
  • 11
  • [ 3132-99-8 ]
  • [ 22483-09-6 ]
  • [ 58794-09-5 ]
  • [ 63927-22-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 22, p. 6378 - 6382
  • 12
  • [ 405161-29-7 ]
  • [ 63927-22-0 ]
Reference: [1] Tetrahedron, 2002, vol. 58, # 29, p. 5761 - 5766
  • 13
  • [ 6630-33-7 ]
  • [ 63927-22-0 ]
Reference: [1] Tetrahedron, 2002, vol. 58, # 29, p. 5761 - 5766
  • 14
  • [ 119-65-3 ]
  • [ 34784-04-8 ]
  • [ 63927-22-0 ]
  • [ 81045-39-8 ]
Reference: [1] Synthesis, 2002, # 1, p. 83 - 86
  • 15
  • [ 119-65-3 ]
  • [ 34784-04-8 ]
  • [ 63927-22-0 ]
  • [ 81045-39-8 ]
Reference: [1] Synthesis, 2002, # 1, p. 83 - 86
  • 16
  • [ 63927-22-0 ]
  • [ 75416-51-2 ]
YieldReaction ConditionsOperation in experiment
98%
Stage #1: at 0℃; for 0.166667 h;
Stage #2: at 0℃; for 5 h;
NaBH3CN (30.20 g, 480.64 mmol) was added to a mixture of 8-bromoisoquinoline(20.00 g, 96.13 mmol) in MeOH (300 mL) at 0 °C. The resulting mixture was stirredfor 10 minutes and Boron trifluoride diethyl etherate (68.22 g, 480.64 mmol) was added dropwise at 0 °C. The resulting mixture was stirred for 1 hour at 0 °C and then refluxed for 4 hours. Sat. Na2CO3 (5 mL) was added and solvent was concentrated under reduced pressure. The remaining liquid was poured into water and extracted withCH2C12. The organic layer was washed with brine, dried over Mg504, filtered and evaporated in vacuo to give 20 g of intermediate 21(98percent yield) which was used in the next step without further purification.
Reference: [1] Patent: WO2017/216293, 2017, A1, . Location in patent: Page/Page column 74
  • 17
  • [ 63927-22-0 ]
  • [ 475994-60-6 ]
Reference: [1] Tetrahedron, 2002, vol. 58, # 29, p. 5761 - 5766
[2] Patent: WO2017/100591, 2017, A1,
  • 18
  • [ 63927-22-0 ]
  • [ 893566-75-1 ]
Reference: [1] Patent: WO2017/216293, 2017, A1,
  • 19
  • [ 63927-22-0 ]
  • [ 1233025-78-9 ]
Reference: [1] Patent: CN108003100, 2018, A,
  • 20
  • [ 63927-22-0 ]
  • [ 121-43-7 ]
  • [ 721401-43-0 ]
YieldReaction ConditionsOperation in experiment
41%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 1 h; Inert atmosphere
Stage #2: at 0℃; for 1 h;
To a solution of 8-bromoisoquinoline (2.0 g, 9.6 mmol) in THE (40 mL) was added dropwise n-BuLi (2.5 M, 4.2 mL, 10.6 mmol) at -78 °C under nitrogen. After 1 hour, B(OMe)3 (2.0 g, 19.2 mmol) was added to the reaction and the mixture was warmed to 0 °C for 1 hour. The reaction was quenched by aqueous NaHCO3 andextracted with EtOAc 3 times. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography to give 75 (680 mg, 41percent) as a slightly yellow solid. LCMS (m/z: m+1):174.1.
Reference: [1] Patent: WO2018/165718, 2018, A1, . Location in patent: Page/Page column 93
  • 21
  • [ 63927-22-0 ]
  • [ 721401-43-0 ]
Reference: [1] Chemistry - A European Journal, 2010, vol. 16, # 45, p. 13528 - 13538
  • 22
  • [ 63927-22-0 ]
  • [ 68-12-2 ]
  • [ 787615-01-4 ]
Reference: [1] ChemMedChem, 2016, vol. 11, # 4, p. 403 - 419
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 63927-22-0 ]

Bromides

Chemical Structure| 58794-09-5

[ 58794-09-5 ]

7-Bromoisoquinoline

Similarity: 0.94

Chemical Structure| 129013-83-8

[ 129013-83-8 ]

3-(4-Bromophenyl)pyridine

Similarity: 0.88

Chemical Structure| 34784-05-9

[ 34784-05-9 ]

6-Bromoisoquinoline

Similarity: 0.87

Chemical Structure| 4373-72-2

[ 4373-72-2 ]

4-(3-Bromophenyl)pyridine

Similarity: 0.85

Chemical Structure| 1192815-02-3

[ 1192815-02-3 ]

7-Bromoisoquinolin-3-amine

Similarity: 0.84

Related Parent Nucleus of
[ 63927-22-0 ]

Isoquinolines

Chemical Structure| 58794-09-5

[ 58794-09-5 ]

7-Bromoisoquinoline

Similarity: 0.94

Chemical Structure| 34784-05-9

[ 34784-05-9 ]

6-Bromoisoquinoline

Similarity: 0.87

Chemical Structure| 1192815-02-3

[ 1192815-02-3 ]

7-Bromoisoquinolin-3-amine

Similarity: 0.84

Chemical Structure| 651310-24-6

[ 651310-24-6 ]

5-Bromo-4-methylisoquinoline

Similarity: 0.81

Chemical Structure| 34784-04-8

[ 34784-04-8 ]

5-Bromoisoquinoline

Similarity: 0.80